---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000131"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:42:19.345454+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zentalis announces azenosertib monotherapy RP2D with 36.8% ORR in ovarian/USC

## Summary
- RP2D set at 400 mg QD on 5:2 schedule; steady-state exposure more than doubled vs continuous dosing.
- Confirmed ORR 36.8% (7/19) in ovarian/USC with intermittent dosing vs 19.2% (5/26) continuous.
- No discontinuations due to TRAEs in intermittent cohorts; improved tolerability over continuous dosing.
- Three Phase 2 monotherapy trials enrolling: Cyclin E1+ ovarian, USC, PARPi-resistant ovarian cancer.
- Company plans H2 2023 update on Phase 1 dose optimization data and Phase 2 program timelines.

## SEC filing metadata
- accession: 0001725160-23-000131
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000131/0001725160-23-000131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000131/zntl-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000131
- JSON: https://secwatch.observer/filing/0001725160-23-000131.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.